Medical Device News Magazine

Clinical Trial Equipment & Ancillary Solutions Market Report 2022-2030: Featuring Key Players Ancillare, Imperial, Thermo Fisher Scientific & Others

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

The “Clinical Trial Equipment & Ancillary Solutions Market Size, Share & Trends Analysis Report by Product (Sourcing, Supply/Logistics), by Phase (Phase I, II, III, IV), by Region (APAC, North America), and Segment Forecasts, 2022-2030″ report has been added to ResearchAndMarkets.com’s offering.

The global clinical trial equipment & ancillary solutions market is expected to reach USD 5.09 billion by 2030, expanding at a CAGR of 8.1% over the forecast period. The growing pharmaceutical and medical sectors, globalization of clinical trials, and rising R&D expenditure are the factors driving the market.

The clinical trial procedure has evolved considerably in recent years. Complex clinical studies are creating new problems throughout the healthcare supply chain. Modern studies frequently involve huge numbers of patients and patient subgroups, as well as numerous nations and research sites.

As a result, the number of challenges that supply chain managers confront while working with clinical trial equipment & ancillaries has increased. Renting medical equipment relieves the burden of storage, retrieval, and disposal. Another important decision-making reason is that renting equipment reduces significant upfront expenses and large investments required to furnish licensed clinical trial locations.

Clinical Trial Equipment & Ancillary Solutions Market Report Highlights

  • The supply/logistics product segment dominated the market with a revenue share of more than 38% in 2021 due to the high number of clinical trials globally, which resulted in increased demand for efficient logistics services.
  • The phase III segment accounted for the maximum revenue share of 53.9% in the global market in 2021. Phase III studies are the most effective approach to discovering a new treatment standard.
  • North America led the global market in 2021 and is expected to remain dominant even during the forecast years due to a rise in the number of CRO and pharmaceutical & medical companies in the region.
  • Asia Pacific is projected to be the registered fastest-growing CAGR of 9.5% during the forecast period as it is becoming an increasingly significant site for clinical trial investigations.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Clinical Trial Equipment & Ancillary Solutions Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Evolving Clinical Trials Needs
3.3.1.2 Rising Investment In R&D
3.3.1.3 Growing Pharmaceutical & Medical Devices Industry
3.3.2 Market Restraint Analysis
3.3.2.1 Rising Cost Of Clinical Trials

Chapter 4 Clinical Trial Equipment & Ancillary Solutions Market: Product Segment Analysis

Chapter 5 Clinical Trial Equipment & Ancillary Solutions Market: Phaseanalysis

Chapter 6 Clinical Trial Equipment & Ancillary Solutions Market: Regional Analysis

Companies Mentioned

  • Ancillare Lp
  • Imperial Crs
  • Woodley Equipment Company Ltd
  • Thermo Fisher Scientific Inc.
  • Ppd, Inc
  • Parexel International Corporation
  • Medicapital Rent (Emsere)
  • Quipment Sas
  • Irm
  • Marken a Ups Company
  • Myonex
  • Yourway

For more information about this report visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”